VYNE Announces 1-for-50 Reverse Split, Updates Special Dividend Ahead of Yarrow Merger
VYNE has more than doubled off its 52-week low of $0.281 on elevated volume (3.8× avg).
Summary
VYNE Therapeutics announced a 1-for-50 reverse stock split and provided an update on the special dividend tied to its pending merger with Yarrow Bioscience. The reverse split is a mechanical step to meet Nasdaq listing requirements post-merger, signaling the deal is progressing toward close. The dividend update clarifies timing or mechanics for the aggregate cash dividend of $17.3 million, or about $0.40242 per share, which was previously declared as $16.5 million ($0.38/share). This follows overwhelming shareholder approval of the merger on July 18 and a recent investor presentation from Yarrow. The reverse split will drastically reduce the share count, potentially increasing volatility and altering the stock's trading dynamics. The merger is expected to close soon, with the combined company focusing on Yarrow's clinical pipeline, including the Phase 2a/2b trial for Graves' disease.
At the time of this announcement, VYNE was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.7M. The 52-week trading range was $0.28 to $1.60. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.